The substantial increase in the price target by a reputable analyst firm like Needham suggests a strong bullish outlook for Cidara Therapeutics. This adjustment reflects a significant positive reassessment of the company's value and prospects, likely based on recent developments or anticipated future performance. Such a dramatic change can positively influence investor sentiment and potentially lead to a short-term increase in stock price as the market adjusts to the new valuation.